Inhibrx Biosciences closed at $86.76 on Nov 4, up 7.01%, 38.8% below its 52-week closing high. Volume of 190.2K shares was 0.61× its 20-day average (below normal).
Split-adjusted performance: -7.1% over one month, -38.8% over six months, +6.5% over one year.
Short interest was 3.4M shares at the Oct 15 settlement (35.5% of float, 16.8 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| INBXInhibrx Biosciences | $86.76 | +7.01% | −38.8% | −100.0% | — | — | $1.28B | |
| VORVor Biopharma | $20.12 | +1.31% | +26.5% | — | — | 0.9 | $1.24B | Compare |
| TSHATaysha Gene Therapies | $4.36 | +6.60% | −37.5% | −100.0% | — | — | $1.42B | Compare |
| ODTXOdyssey Therapeutics | $19.50 | −9.60% | — | — | — | — | $937.1M | Compare |
| NVAXNovavax | $10.65 | +10.02% | +13.8% | −76.3% | −94.2% | — | $1.76B | Compare |
| GLUEMonte Rosa Therapeutics | $10.82 | +3.94% | −46.9% | −61.3% | −483.9% | — | $923.1M | Compare |
| MGTXMeiraGTx Holdings | $9.42 | −1.05% | −4.8% | +8608.6% | 50.0% | 11.5 | $904.7M | Compare |
| PRMEPrime Medicine | $4.97 | +9.23% | +45.7% | +3.5% | −3649.0% | — | $901.4M | Compare |
| MAZEMaze Therapeutics | $33.38 | +3.50% | +26.1% | — | — | — | $1.85B | Compare |
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
